NAFDAC Orders Recall of Deekins Amoxycillin Capsules After Multiple Adverse Reactions

The National Agency for Food and Drug Administration and Control (NAFDAC) has issued an alert regarding the recall of one batch of Deekins Amoxycillin 500mg Capsules, manufactured by Ecomed Pharma Ltd and marketed by DevineKings Pharmaceutical Ltd.

EKO HOT BLOG reports that the affected batch, identified by lot number 4C639001, is being recalled following reports of serious adverse drug reactions.

According to a report from Ecomed Pharma Ltd, three cases of serious adverse drug reactions were reported by a hospital involving patients who had been administered the batch of Deekins Amoxycillin 500mg capsules.

Amoxicillin, a penicillin antibiotic, is commonly used to treat bacterial infections, including tonsillitis, bronchitis, pneumonia, and infections of the ear, nose, throat, skin, or urinary tract.

EDITOR’S PICKS 

• Electricity Meter Costs Rise Again As Deregulation Takes Effect
• Biden, Harris Set To Congratulate Trump On Presidential Win
• Thousands Of ‘Trained’ Combatants Ready To Fight Israel – Hezbollah Chief

NAFDAC warned that adverse reactions to the drug could be life-threatening and may require hospitalization, lead to persistent disability or incapacity, or even result in birth defects or death in fatal cases.

The affected product details are as follows: Name: MAH manufactured by Ecomed Pharmaceutical Ltd. Days of manufacturing is 03/2024, Expiry date: 02/2027 and batch number : 4C639001.

NAFDAC urged distributors, healthcare providers, and patients to remain vigilant and avoid distributing, administering, or using the affected lot. The agency emphasized that medical products should only be obtained from authorized/licensed suppliers, and the authenticity and physical condition of the products should be carefully checked.

FURTHER READING

• Hezbollah Launches 120 Projectiles From Lebanon Into Israel
• Full List of Chief of Army Staff Who Died in Office
• ECOWAS Court Partners ICRC To Domesticate International Humanitarian Law

Consumers and healthcare professionals in possession of the affected batch are advised to immediately discontinue its sale or use and return any stock to the nearest NAFDAC office. Those who have used the product or know someone who has experienced any adverse reactions are advised to seek immediate medical advice from a healthcare professional.

NAFDAC encourages the reporting of any substandard or falsified medicines to the nearest NAFDAC office or via the agency’s contact line at 0800-162-3322 or email at sf.alert@nafdac.gov.ng.

Healthcare professionals and patients can also report adverse events or side effects using NAFDAC’s E-reporting platforms on its website.

Click here to watch our video of the week: